Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PADI4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PADI4 Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for enzymatic and binding assays. |
View PADI4 Products |
| Gene Delivery | PADI4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View PADI4 Products |
| Benchmark Ab | Anti-PADI4 Recombinant Antibody Recombinant positive control for assay validation and target detection. |
View PADI4 Products |
| Validator | PADI4 siRNA Set For knockdown verification in functional and phenotypic assays. |
View PADI4 Products |
| Related Target A | PADI2 Critical homolog for selectivity counter-screening to prevent off-target toxicity. |
View PADI2 Products |
| Related Target B | MPO (Myeloperoxidase) Synergistic marker in Neutrophil Extracellular Traps (NETs) formation and inflammatory pathways. |
View MPO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PAD Family Selectivity (PAD4 vs PAD2) | Homolog panel proteins (PADI4 and PADI2) strictly verified by mass spectrometry and sequence verification. |
| Calcium-Dependent Conformation Integrity | Recombinant proteins designed for native calcium-binding structural integrity, ensuring physiological relevance in screening. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| False Positive Screening Results | Validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live PADI4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PADI4 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted inhibition of citrullination. As first-generation small molecule inhibitors reach clinical evaluation, the next wave of R&D is targeting the prevention of Neutrophil Extracellular Traps (NETs) in autoimmune diseases, cardiovascular disorders, and cancer immunotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Bristol Myers Squibb, GSK, Pfizer | Rheumatoid Arthritis, Lupus | Selectivity Assay (Need high-purity PADI4 & PADI2 mutant/WT proteins) |
| Monoclonal Antibody | Academic & Biotech Consortia | Oncology (NETosis prevention) | Epitope Mapping & Binding Assay (Need sequence-verified antigens) |
| Gene Therapy / RNAi | Preclinical Discovery Programs | Inflammatory Disorders | Knockdown Validation (Need validated PADI4 siRNA & Lentivirus) |